Phase I Clinical Trial of Intracerebroventricular Transplantation of Allogeneic Neural Stem Cells in People with Progressive Multiple Sclerosis

Scientists reported the analysis of one year of data from the first cohort of 15 patients enrolled in an open-label, first-in-human, dose-escalation Phase I study to determine the feasibility, safety, and tolerability of the transplantation of allogeneic human neural stem/progenitor cells for the treatment of secondary progressive multiple sclerosis.